ArticleGenes, chromosomes & cancer2014
Exomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomas.
Article in Genes, chromosomes & cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 105 citations in OpenAlex.
- Understanding and Overcoming Osteosarcoma Heterogeneity.Biomolecules · 2026Review
- Spectrum and Clinical Impact of Secondary Genetic Alterations in Translocation-Associated Sarcomas.JCO precision oncology · 2025Article
- Intratumoral heterogeneity of cancer driver genomic alterations in myxoid liposarcomas.Cancer · 2025Article
- SETD2 loss-of-function uniquely sensitizes cells to epigenetic targeting of NSD1-directed H3K36 methylation.Genome biology · 2025Article
- Improved Quantification of Circulating Tumor DNA in Translocation-Associated Myxoid Liposarcoma by Simultaneous Detection of Breakpoints and Single Nucleotide Variants.Cancer medicine · 2025Article
- Targeting myeloid-derived suppressor cells in the tumor microenvironment: potential therapeutic approaches for osteosarcoma.Oncology research · 2025Review
- FUS::DDIT3 Fusion Protein in the Development of Myxoid Liposarcoma and Possible Implications for Therapy.Biomolecules · 2024Review
- Myxoid liposarcoma with nuclear pleomorphism: a clinicopathological and molecular study.Virchows Archiv : an international journal of pathology · 2024Article
- Identification of mHeliyon · 2023Article
- Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario.Pharmaceutics · 2023Review
- Review
- Targeted next-generation sequencing of circulating free DNA enables non-invasive tumor detection in myxoid liposarcomas.Molecular cancer · 2022Article
- Radiation-Induced Phosphorylation of a Prion-Like Domain Regulates Transformation by FUS-CHOP.Cancer research · 2021Article
- The oncogenic transcription factor FUS-CHOP can undergo nuclear liquid-liquid phase separation.Journal of cell science · 2021Article
- Soft Tissue Sarcoma: An Insight on Biomarkers at Molecular, Metabolic and Cellular Level.Cancers · 2021Review
- The epigenomics of sarcoma.Nature reviews. Cancer · 2020Review
- BRAF V600E mutation is a potential therapeutic target for a small subset of synovial sarcoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020Article
- Molecular Biology of Osteosarcoma.Cancers · 2020Review
- Gene Prioritization through Consensus Strategy, Enrichment Methodologies Analysis, and Networking for Osteosarcoma Pathogenesis.International journal of molecular sciences · 2020Article
- Absence of H3F3A mutation in a subset of malignant giant cell tumor of bone.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2019Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 3 countries.
Funding
Abstract
Bone and soft tissue sarcomas are a group of histologically heterogeneous and relatively uncommon tumors. To explore their genetic origins, we sequenced the exomes of 13 osteosarcomas, eight myxoid liposarcomas (MLPS), and seven synovial sarcomas (SYN). These tumors had few genetic alterations (median of 10.8). Nevertheless, clear examples of driver gene mutations were observed, including canonical mutations in TP53, PIK3CA, SETD2, AKT1, and subclonal mutation in FBXW7. Of particular interest were mutations in H3F3A, encoding the variant histone H3.3. Mutations in this gene have only been previously observed in gliomas. Loss of heterozygosity of exomic regions was extensive in osteosarcomas but rare in SYN and MLPS. These results provide intriguing nucleotide-level information on these relatively uncommon neoplasms and highlight pathways that help explain their pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.